

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>BridgeBio Pharma LLC</u> (Last) (First) (Middle) <u>421 KIPLING ST</u> (Street) <u>PALO ALTO CA 94301</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>06/19/2018</u>	3. Issuer Name and Ticker or Trading Symbol <u>Eidos Therapeutics, Inc. [EIDX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Series Seed Preferred Stock</u>	(1)	(1)	<u>Common Stock</u>	<u>15,347,219</u>	(1)	<u>D</u>	
<u>Series B Preferred Stock</u>	(1)	(1)	<u>Common Stock</u>	<u>3,081,813</u>	(2)	<u>D</u>	
<u>Warrants</u>	(2)	(2)	<u>Series B Preferred Stock</u>	<u>332,262</u>	<u>10.8348</u>	<u>D</u>	

Explanation of Responses:

- The preferred stock will automatically convert into the Issuer's Common Stock on a 1-to-1.196 basis upon the closing of the Issuer's initial public offering and has no expiration date.
- Immediately prior to completion of the Issuer's initial public offering, the warrants will automatically be exercised for shares of Series B Preferred Stock and such shares acquired will automatically be converted into shares of the Issuer's Common Stock on a 1 to 1.196 basis, net of shares of Common Stock withheld by the Issuer to cover the exercise price, resulting in the issuance of 185,623 shares of Common Stock.

Remarks:

BridgeBio Pharma LLC By: /s/ Neil Kumar, Chief Executive Officer 06/19/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.